2,2',4,4',5-Pentabromodiphenyl ether


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:C563515 Neutrophil Chemotactic Response, Abnormal PMID:24451063
MESH:D001724 Birth Weight PMID:21663933; PMID:32938446
MESH:D001848 Bone Diseases, Developmental PMID:22331496
MESH:D006319 Hearing Loss, Sensorineural PMID:21873374
MESH:D006332 Cardiomegaly PMID:22331496
MESH:D006529 Hepatomegaly PMID:22331496
MESH:D007674 Kidney Diseases PMID:20223270
MESH:D007859 Learning Disabilities PMID:23578391
MESH:D009358 Congenital, Hereditary, and Neonatal Diseases and Abnormalities PMID:30978398
MESH:D009422 Nervous System Diseases PMID:22323513
MESH:D011041 Poisoning PMID:22323513
MESH:D011297 Prenatal Exposure Delayed Effects PMID:21663933; PMID:23578391
MESH:D019954 Neurobehavioral Manifestations PMID:17982161
MESH:D056486 Chemical and Drug Induced Liver Injury PMID:20223270; PMID:23124135

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.